靶向核素探针指导乳腺癌临床诊疗研究进展
Progress of targeted nuclide probes in guiding clinical diagnosis and treatment of breast cancer
裴一飞 1白静雯 2朱华 3杨志3
作者信息
- 1. 福建省乳腺癌精准诊治重点实验室,厦门大学医学院,福建厦门 361111;北京大学肿瘤医院暨北京市肿瘤防治研究所核医学科,消化系肿瘤整合防治全国重点实验室,国家药品监督管理局放射性药物研究与评价重点实验室,恶性肿瘤发病机制及转化研究教育部重点实验室,北京 100142
- 2. 福建省乳腺癌精准诊治重点实验室,厦门大学医学院,福建厦门 361111
- 3. 北京大学肿瘤医院暨北京市肿瘤防治研究所核医学科,消化系肿瘤整合防治全国重点实验室,国家药品监督管理局放射性药物研究与评价重点实验室,恶性肿瘤发病机制及转化研究教育部重点实验室,北京 100142
- 折叠
摘要
乳腺癌作为异质性很高的恶性肿瘤,以正电子发射体层成像(positron emission tomography,PET)和单光子发射计算机体层成像(single-photon emission computed tomography,SPECT)为基础的分子功能成像能为乳腺癌的精准诊断提供重要依据.临床最常用的显像剂18F-FDG对于乳腺癌的显像存在一定局限性,因此对于新型核素探针的研发如火如荼,包括原位肿瘤成像和远处转移病灶的成像.本文综述了放射性标记探针在乳腺癌诊断和治疗中的最新进展,重点关注靶向肿瘤细胞表面特异性靶点和新近发现的肿瘤微环境靶点,并分类描述了其在临床应用中的实际效果.
Abstract
Breast cancer is a highly heterogeneous malignancy,and molecular functional imaging techniques such as positron emission tomography(PET)and single-photon emission computed tomography(SPECT)play a critical role in its accurate diagnosis.While imaging provides a crucial foundation for precise breast cancer diagnosis,the most used imaging agent,18F-FDG,presents certain limitations in this context.Consequently,there has been an increased focus on the research and development of novel radiolabeled probes for both in situ imaging of primary tumors and the detection of distant metastases.This paper reviewed the recent advancements in radiolabeled probes for breast cancer diagnosis and treatment,with an emphasis on novel targets that exploit specific surface markers on tumor cells and elements of the tumor microenvironment and categorized their practical applications in clinical settings.
关键词
乳腺癌/核医学/正电子发射体层成像/单光子发射计算机体层成像Key words
Breast cancer/Nuclear medicine/Positron emission tomography/Single photon emission computed tomography引用本文复制引用
基金项目
首都卫生发展科研专项(2022-2Z-2154)
首都卫生发展科研专项(2022-2Z-2155)
出版年
2024
NETL
NSTL
万方数据